Shares Investor Evening (Manchester) - EVENT POSTPONED

Presenting

  • Fulham Shore

    Fulham Shore

    Founded in 2012 and admitted to AIM in 2014, Fulham Shore (FUL) owns and operates The Real Greek and Franco Manca restaurant brands.

  • Kore Potash

    Kore Potash

    Kore Potash is an advanced stage mineral exploration and development company whose primary asset is 97%-owned interest in the Sintoukola project, a potash project located in the Republic of Congo.

  • PCF Bank

    PCF Bank

    PCF Bank (PCF) was established in 1994, PCF Group plc is a long established bank, whose shares are quoted on the AIM market of the London Stock Exchange.

  • STV Group

    STV Group

    STV Group plc is Scotlands home of news, entertainment and drama, providing audiences with top-quality programming on air, online and on demand.

    STV is the most popular peak time TV channel in Scotland, reaching 3 million viewers each month. Fast-growing free streaming service, STV Player, is available on all major platforms offering UK viewers an extensive catalogue of content. Award-winning production group STV Studios makes shows for broadcasters and streamers including prison drama Screw, police drama Blue Lights and quiz format Bridge of Lies

  • SkinBioTherapeutics

    SkinBioTherapeutics

    SkinBioTherapeutics is a life science company focused on skin health. The Companys proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine ONeill and Professor Andrew McBain at The University of Manchester.

    The SkinBioTherapeutics platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.

    SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas SkinBioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept.